EAPA Lone Star

Digital Therapeutics - New Trends

  • 15 Sep 2021
  • 11:30 AM - 1:00 PM
  • Virtual Meeting - Webinar

 

Global Digital Therapeutics Market influenced by technological innovations and arrangement described in a new report - WhaTech

Newest Trends in Digital Therapeutics 

About this Event

This is a virtual meeting.

FREE Registration is by invitation through Eventbrite.

Contact eapa.lonestar@gmail.com to get on our email list.

Click Here to be Redirected to Registration

Topic:

Depression, Problematic Drinking, Opioid Use Disorder, and the Role of Digital Therapeutics – Overview

Speaker

Dr. Shweta Patel (Medical Director, Orexo, US)

Session Educational Summary:

There is an evolution occurring in how digital technology is advancing and being used to support the delivery of mental and behavioral health care. The COVID-19 pandemic brought mental health and gaps in mental health care to the forefront in the areas of depression and substance use disorders. Digital therapeutics represent one potential tool that can be used to address these gaps in care. By the end of this session, participants will demonstrate an understanding of common mental health issues facing the American workforce and how digital therapeutics can help to address these issues. Orexo’s digital therapeutic deprexis® will provide a tangible example of just one mental health digital therapeutic.

Learning Objectives:

  • Participants will be able to demonstrate an understanding of depression, problematic drinking, and opioid use disorder, and how these mental health issues impact the workforce.
  • Participants will be able to describe digital therapeutics in the mental health space, and they will be able to use deprexis as an example of just one mental health digital therapeutic.
  • Participants will be able to assess the clinical data supporting the use of digital therapeutics with a particular focus on Orexo’s digital therapeutics deprexis® and vorvida®.

About our Speaker

Dr. Shweta Patel (Medical Director, Orexo, US)

Shweta holds a Bachelor’s degree in Computer Science and Biology from George Washington University, as well a Medical Degree from Medical University of Silesia.

She is a driven, energetic physician with over 14 years of broad experience in medical affairs, communications, managed markets, and health policy, with a unique understanding of the medical and commercial aspects of the pharmaceutical industry. She brings us a tremendous amount of experience with leadership roles at Shire, Takeda, CSL Behring and Baxter Healthcare, where she launched several prominent products in rare disease.

Shweta developed and executed global medical strategies for ADVATE, one of the top products globally for Hemophilia A patients. Shweta also helped launch both IDELVION® and AFSTYLA® for adults and children with hemophilia A within 90 days of each other. She has acted as a national medical affairs specialist for outcomes based scientific exchange with payers and organizations, research, education, and external medical professional interchange. As well as implemented the medical affairs plans related primarily to KOL engagement and data dissemination for the USA.




Depression, Problematic Drinking, Opioid Use Disorder, and the Role of Digital Therapeutics – Overview
© EAPA Lone Star
Powered by Wild Apricot. Try our all-in-one platform for easy membership management